Fig. 4
From: Association between weight loss and mortality in idiopathic pulmonary fibrosis
Effect of anti-fibrotic medications on weight loss and transplant-free survival. Patients taking anti-fibrotic medications demonstrated similar weight loss compared with those not taking anti-fibrotic medications. Red lines: pirfenidone, Green lines: nintedanib (A). There was slightly more weight loss observed in those taking nintedanib, however this did not reach statistical significance. There was no statistically significant difference in transplant-free survival between patients taking anti-fibrotic medications and those who were not (p = 0.56) (B). When patients were stratified by degree of weight loss in the first year from diagnosis, there remained no significant difference based on anti-fibrotic medications (C)